Pygeum — Research Profile

Both have moderate-to-strong evidence for BPH symptom relief, but they work through different mechanisms. Pygeum primarily targets inflammation (via triterpenes) and growth factor inhibition, while saw palmetto primarily inhibits 5-alpha-reductase (reducing DHT). Many urologists and European phytotherapy guidelines recommend combining them for comprehensive prostate support, as they address complementary pathological pathways. Pygeum has stronger Cochrane-level evidence, while saw palmetto has more individual RCTs.

This is an important concern. Prunus africana is listed under CITES Appendix II due to overharvesting of wild trees in Cameroon, Madagascar, and other African countries. When purchasing pygeum supplements, look for products that source from sustainably managed plantations or CITES-certified suppliers. Some manufacturers have established replanting programs. This is a supplement where ethical sourcing matters — overharvesting threatens both the species and the communities that depend on it.

Most clinical trials show measurable improvements in urinary symptoms within 4-8 weeks. The Cochrane-reviewed trials used treatment periods of 30-120 days, with benefits typically apparent by 6-8 weeks. Pygeum is intended for ongoing use rather than acute symptom relief — consistent daily dosing is important. Some men notice improvements in nocturia (nighttime urination) within the first 2-4 weeks.

The form with clinical support is the fat-soluble (lipophilic) bark extract standardized to 14% triterpenes and 0.5% n-docosanol, taken as a capsule. This is what the randomized trials used; unstandardized bark powder, teas, or tinctures have not been tested for benign prostatic hyperplasia. There is no evidence that any alternative preparation outperforms the standardized lipophilic extract.

The best evidence is a Cochrane meta-analysis of 18 randomized trials in 1,562 men with benign prostatic hyperplasia: pygeum users were about twice as likely to report overall symptom improvement (RR 2.1), with roughly 19% less nocturia, 23% higher peak urine flow, and 24% lower residual urine volume versus placebo. These benefits are modest and the trials were short, small, and often had high placebo responses, and none compared pygeum head-to-head with standard BPH drugs. Its documented use is limited to easing mild-to-moderate lower urinary tract symptoms, not shrinking the prostate.

Clinical trials of standardized Pygeum africanum bark extract have most often used 100 mg per day. A randomized, double-blind trial in 209 men with benign prostatic hyperplasia found that 100 mg once daily and 50 mg twice daily were equally effective and equally well tolerated over two months, so either schedule is reasonable. No single optimal dose has been formally established, and standardized products generally cluster around this 100 mg daily amount.

Time of day has not been directly compared in pygeum trials, which simply dosed the extract once or twice daily without specifying morning or evening. A randomized trial found 100 mg once daily and 50 mg twice daily equally effective, so whether you split the dose or take it all at once is a matter of convenience rather than efficacy. Because the main reported side effects are mild nausea and abdominal discomfort, taking it with food is a reasonable way to reduce stomach upset.

Side effects are uncommon and mild, almost entirely gastrointestinal, chiefly nausea and abdominal pain. In the pooled randomized trials, adverse effects with pygeum were comparable to placebo, and study dropout rates were similar between groups (13% vs 11%). Serious adverse events were not a feature of the trial data.

No specific drug interactions with pygeum have been documented, and it has not been formally studied for interactions. That absence reflects limited testing rather than proven safety, so men already taking prostate medications such as alpha-blockers or 5-alpha-reductase inhibitors should treat combined use as unstudied. Anyone on prescription drugs should confirm with a pharmacist before adding it.

Pygeum is aimed at men with mild-to-moderate benign prostatic hyperplasia who want a plant option for lower urinary tract symptoms like nighttime urination and weak flow. It is not a substitute for medical evaluation, since urinary symptoms can have other causes, and the evidence base is modest rather than definitive. It has no established role for women and has not been evaluated in pregnancy or breastfeeding.

Onset has not been precisely characterized for pygeum. The randomized trials pooled in the Cochrane meta-analysis ran a mean of about 64 days (range 30-122 days), and that is the window over which improvements in nocturia and urine flow were measured rather than a proven time-to-effect. If a standardized bark extract is going to help lower urinary tract symptoms, expect to give it several weeks before judging benefit.

Controlled safety data only extend to roughly the trial lengths studied, which topped out at about 122 days (four months). Across those trials adverse effects were mild and no more frequent than placebo (13% vs 11% dropout), but tolerability and safety beyond about four months of continuous use have not been formally established. Pygeum is a men's BPH remedy and has not been evaluated in pregnancy or breastfeeding.

No toxic threshold or upper limit has been defined for pygeum. Trials used 75-200 mg/day of standardized extract, and the main effect of taking more is gastrointestinal upset rather than organ toxicity. Reported adverse effects are limited to mild nausea and abdominal pain, so there is no evidence that pushing above the studied range adds benefit.

Pygeum is commonly formulated alongside saw palmetto (Serenoa repens), pumpkin seed, and beta-sitosterol, and no supplement or food interactions with pygeum have been documented. However, combination products cannot show what pygeum itself adds: a 2025 trial pairing pygeum with L-cystine, saw palmetto, and pumpkin seed studied hair growth, not prostate symptoms, and could not isolate any single ingredient. There is no evidence that stacking pygeum with other botanicals improves BPH outcomes over the standardized extract alone.

Look for a lipophilic bark extract of Prunus africana (Pygeum africanum) standardized to about 14% triterpenes (including beta-sitosterol) and 0.5% n-docosanol, which is the specification used in the BPH clinical trials. Products that list only raw powdered bark or omit the standardization percentages have not been the ones tested for urinary symptoms. Because the tree is a protected species, reputable brands should also indicate sustainable or cultivated sourcing.